Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Monday, June 8, 2026 1 min read

Key Takeaway: Septerna is set to present the preclinical characterization of SEP-479, an oral PTH1R agonist aimed at treating hypoparathyroidism. This presentation will take place at the 2026 ENDO Annual Meeting. Details about the drug's efficacy and safety profile are expected to be discussed during the event.